SERA News

After a slow start to the month, the IPO market revved back to life with 13 IPOs coming to market this past week. SPAC activity picked up, with seven blank check IPOs raising $940 million. New filers continued to flood the IPO pipeline, with fourteen IPOs and nine SPACs submitting initial filings.   Italian drug container supplier Stevanato Group (STVN)...read more

Sera Prognostics, which develops diagnostic tests for pregnancy complications, raised $75 million by offering 4.7 million shares at $16, within the range of $15 to $17. Sera Prognostics uses its proprietary proteomics and bioinformatics platform to develop pregnancy and other women's health biomarker tests. The company's commercial product, the PreTRM test, is the only broadly...read more

Updated Monday, 7/12. After a slow holiday week, 15 IPOs are scheduled to raise nearly $4 billion in the week ahead. A handful of SPACs should also price. Italian drug container supplier Stevanato Group (STVN) plans to raise $900 million at a $6.8 billion market cap. Controlled by its founding family, the profitable company supplies glass vials,...read more

Sera Prognostics, which develops diagnostic tests for pregnancy complications, announced terms for its IPO on Thursday. The Salt Lake City, UT-based company plans to raise $75 million by offering 4.7 million shares at a price range of $15 to $17. At the midpoint of the proposed range, Sera Prognostics would command a fully diluted market value of $564 million. Sera...read more